Charles Schwab Could Swing $6.23 Billion After Earnings
Eight stocks reporting Thursday face earnings-driven volatility, with options markets pricing in implied moves ranging from 3.67% to 10.80%, according to Benzinga Pro.
Stocks · News reference
Earnings Scheduled For July 16, 2026
Companies Reporting Before The Bell • U.S. Bancorp (NYSE:USB) is likely to report quarterly earnings at $1.27 per share on revenue of $7.59 billion. • New Horizon Aircraft (NASDAQ:HOVR) is expected to report earnings
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of precious metals-related companies are trading lower after stronger-than-expected inflation data boosted expectations for a Federal Reserve rate hike in October. Gold and silver prices are declining amid a stronger U.S. dollar and rising Treasury yields, which make non-yielding precious metals less attractive to investors.
Barclays Initiates Coverage On Alcoa with Overweight Rating, Announces Price Target of $55
JP Morgan Maintains Neutral on Alcoa, Lowers Price Target to $50
JP Morgan analyst Bill Peterson maintains Alcoa (NYSE:AA) with a Neutral and lowers the price target from $52 to $50.
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight
The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure.
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell
The article recommends two Dividend King healthcare stocks for passive income: Abbott Laboratories and Johnson & Johnson. Both companies have demonstrated 50+ years of consecutive dividend increases, strong free cash flow, diversified business portfolios, and solid growth prospects. Abbott offers a 2.5% dividend yield with innovative products like the Libre Duo glucose monitor, while J&J pays a 2% yield and is positioned to reach $100 billion in annual revenue with a strong oncology pipeline.